Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PBP-3 directed therapy in VIM-producing Pseudomonas aeruginosa creates bacterial transformers, persisters in disguise.

Autor: Smith NM; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: nmsmith2@buffalo.edu., Boissonneault KR; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Holden PN; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Kaur JN; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Klem JF; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Cha R; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Sutton MD; Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA., Tsuji BT; Division of Clinical and Translational Therapeutics, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: btsuji@buffalo.edu.

Publikováno v: International journal of antimicrobial agents [Int J Antimicrob Agents] 2024 Sep; Vol. 64 (3), pp. 107260. Date of Electronic Publication: 2024 Jun 28.

Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.

Autor: Smith NM; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA., Boissonneault KR; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA., Chen L; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA., Petraitis V; Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA., Petraitiene R; Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA., Tao X; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA., Zhou J; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA., Lang Y; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA., Kavaliauskas P; Transplantation-Oncology Infectious Disease Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA., Bulman ZP; Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA., Holden PN; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA., Cha R; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA., Bulitta JB; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Floridagrid.15276.37, Orlando, Florida, USA., Kreiswirth BN; Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA., Walsh TJ; Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.; Department of Pediatrics, Weill Cornell Medicine of Cornell University, New York, New York, USA.; Department of Microbiology & Immunology, Weill Cornell Medicine of Cornell University, New York, New York, USA.; Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA., Tsuji BT; Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; New York State Center of Excellence in Life Sciences and Bioinformatics, Buffalo, New York, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Sep 20; Vol. 66 (9), pp. e0052722. Date of Electronic Publication: 2022 Aug 04.

Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.

Autor: Lodise TP; Albany College of Pharmacy and Health Sciences, Albany, NY, USA., Smith NM; Laboratory for Antimicrobial Pharmacodynamics, University at Buffalo, Buffalo, NY, USA., O'Donnell N; Albany College of Pharmacy and Health Sciences, Albany, NY, USA., Eakin AE; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Holden PN; Laboratory for Antimicrobial Pharmacodynamics, University at Buffalo, Buffalo, NY, USA., Boissonneault KR; Laboratory for Antimicrobial Pharmacodynamics, University at Buffalo, Buffalo, NY, USA., Zhou J; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA., Tao X; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA., Bulitta JB; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA., Fowler VG; Division of Infectious Diseases, Duke University, Durham, NC, USA.; Duke Clinical Research Institute, Duke University, Durham, NC, USA., Chambers HF; University of California, San Francisco, and San Francisco General Hospital, San Francisco, CA, USA., Bonomo RA; Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA; Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, OH, USA., Tsuji BT; Laboratory for Antimicrobial Pharmacodynamics, University at Buffalo, Buffalo, NY, USA.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Sep 01; Vol. 75 (9), pp. 2622-2632.